Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

脏癌症是什么? 脏癌症是什么

N J Vogelzang1, W M Stadler

  • 1University of Chicago Medical Center, Section of Hematology/Oncology, IL 60637-1470, USA. njvogelz@mcis.bsd.uchicago.edu

Lancet (London, England)
|December 16, 1998
PubMed
概括
此摘要是机器生成的。

癌发病率正在上升,特别是在老年男性中. 目前对转移性癌的治疗方法有限,但正在研究新的疗法.

相关实验视频

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

BMC cancer·2021
Same author

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Cancer treatment and research communications·2019
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
查看所有相关文章

科学领域:

  • 在瘤学瘤学.
  • 泌尿器科 泌尿器科 泌尿器科 泌尿器科

背景情况:

  • 自1973年以来,癌发病率在美国显著上升.
  • 风险因素包括男性性别和年龄的增加.
  • 希佩尔-林道瘤抑制基因在零星情况下经常被禁用.

研究的目的:

  • 审查目前对癌的理解和治疗.
  • 突出管理转移性疾病的挑战.
  • 讨论新兴的治疗策略.

主要方法:

  • 关于癌流行病学和治疗的文献综述.
  • 对早期和转移性疾病的当前治疗选择的分析.
  • 目前正在进行的临床研究的概述.

主要成果:

  • 早期的癌是通过切除术来治疗的.
  • 转移性疾病在诊断时存在于20-30%的患者中.
  • 对转移病例 (5-8%) 来说,介质素-2 提供了有限的长期存活率.

结论:

  • 转移性癌的治疗仍然具有挑战性.
  • 针对局部转移和血栓的手术干预至关重要.
  • 对抗血管生成药物等新型药物的积极研究为未来提供了希望.